

()

Continuing Education Column

기능성 소화불량증

Functional Dyspepsia

146 - 92

Sang In Lee, M.D.

Department of Internal Medicine

Yonsei University College of Medicine, Yong - Dong Severance Hospital

E - mail : leesi96@yumc.yonsei.ac.kr

Abstract

Functional dyspepsia (FD) is a complex disease reaction that occurs due to the presence of various factors, and its pathophysiology has not been clearly understood yet. FD is a diagnosis of exclusion after ruling out organic diseases. Therefore, the main treatments are limited to relieving symptoms through supportive care. The international prevalence of FD based on the Rome I criteria is approximately 25%. In Korea, there are very omnifarious symptoms in gastrointestinal disorders, and the medical vocabularies that describe the diagnostic standard are not closely associated with the daily vocabularies., Thus there would be a lot of restrictions in direct application of the Rome II criteria. However, the Korean Society of Gastrointestinal Motility had decided to promote the use of the international standardized Rome II criteria to be comparable to the clinical studies from other nations. There should be more extensive studies to differentiate the definitions of symptoms in Korea from those in other countries. The extended researches concerning the pathophysiology of FD are needed to find reliable treatment modalities for the disease.

Keywords : **Functional dyspepsia; Rome II criterior;**
Visceral hypersensitivity; Helicobacter pylori;
Prokinetic agents

: ; II; ; *Helicobacter pylori*;

(organic)'

20

가

가

가

가

II 가 15.5% , 15.0%, 16.0% (1).

(2).

가 .

가 , .

가 , . 72%

가 , 33.8%, 30.8% .

40.0% (1).

I II 3

II 가 207

가 가 68 (40.5%) 가 , 42 (25.0%)

43 (63.2%), 7 (4.2%), 18 (26.5%) 가

(2). 3

가

2.7~38% (3).

3

1,799

39%가 가 , 가
89%가 . 가 가
(4). 가 .

1. , ,
가
(8). (sensitiza-
tion)

3. (Inflammation)
30~50%
가 가 가
(5). 가 (9). 가
(6). 3 1 (10).

2. (Visceral Hypersensitivity)
(function-
al chest pain)
가
(7).

4. (Brain - Gut Interaction)
(11).

(mood), (central pain perception), PET, fMRI

5. (Brain - Gut Peptides) (5).

(5). 가 5 - hydroxytryptamine, enkephalin, substance P, calcitonin gene related polypeptide opioid

2 3 가 가 가 가 가 가

6. 가 (13). 가 가 가 가 40

(12). 가 (14, 15). 가

가 가

가 (13), . Delaney(23)
3 2 45
(13)가 , 45
. 4 4
Helicobacter pylori
. McColl (16) *Helicobacter pylori*가 가
가 , 가
Blum (17) Talley (18) 가
. 1999 Talley(19)

Helicobacter pylori 1.
(20). 1994 NIH 가
“ *H. pylori*”
H. pylori
(21). *H. pylori* .
1996 10 가
9 *H. pylori* work- 가 .
shop *H. pylori* ,
NIH 가
. Ofman (22) *H. pylori* . (placebo) 13~73%
H. pylori 가
(24).
가
가가 가
. *H. pylori* .
60% *H. pylori* , 가 가 가

1)

가 가 .
가

가가 , H₂

가 가

(25). 가 H₂

. H₂

proton pump inhibitor

(omeprazole, lansoprazole, pantoprazole)

20~30%

H₂ (6).

(, 2003)

(

가

가), 가

가

2 가 .

proton pump inhibitor가

가 .

가 .

가

가 2)

가 . Domperidone, mosapri-
de, metoclopramide, levosulpiride, itopride, ery-
thromycin

2.

가

Cisapride

QT

(limbic system)

가

prostaglandin analogues(Mi-
soprostol), somatostatin analogues(Octreotide);
cholecystokinin antagonists(Loxiglumide), nitric
oxide가 glyceryl
trinitrite nitric oxide releaser 가
(26, 27).

serotonin reuptake inhibitor(fluoxetine, ser-
traline, paroxetine) 가

가

(28) cisapride 4
6 27%가
가

4) :
(1) 5 - hydroxytryptamine(5 - HT)
5 - HT
(serotonin)
(enterochromaffin)

3)

5 - HT₃
(unmyelinated neuron)
. 5 - HT 5 - HT₃ 가
5 - HT₃
(granisetron)

가

(ondansetron)

(29).
가
(amtryptiline, imipramine, doxepine)
serotonin norepinephrine reuptake

가 (30) 5 -
HT₃
(31).

가 (32)

- (33). Tegaserod, alosetron, prucalopride
 5-HT₄ 수용체 작용제 (agonist) 가 II
 (2) (Opioid Substance) 가 II
 , ,
 ,
 가
 μ , 가
 가 (37).
 가
 가
 가
 (treatment on demand)
- (34).
 (3) (CCK Antagonist) 가
 가
- (35). - B 가 II
 - A 가
- (36). 가
 (4) (Somatostatin Analogues) 가
 가

1. *Gastroenterology* 2000; 6: 31 - 43
2. *Gastroenterology* 2003; 41: 183 - 9
3. *Gastroenterology* 1998; 4: 1 - 12
4. Choi H, Choi MG, Kim SW, Moon SB, Kim BK, SUN HS, et al. Functional gastrointestinal disorders in patients with gastrointestinal symptoms. *Korean J Gastroenterol* 1999; 33: 741 - 8
5. Drossman DA. The functional gastrointestinal disorders and the Rome II process. *Gut* 1999; 45(suppl II): 111 - 5
6. *Gastroenterology* 2000; 43: 1131 - 41
7. Mayer EA, Gebbart GF. Basic and clinical aspects of visceral hyperalgesia. *Gastroenterology* 1994; 107: 271 - 93
8. Manakata J, Naliboff B, Harraf E, Konder A, Lembo T, Mayer EA, et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. *Gastroenterology* 1997; 112: 55 - 63
9. Collins SM. Is the irritable gut an inflamed gut? *Scand J Gastroenterol* 1992; 27(suppl 192): 102 - 5
10. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Read NW, et al. The role of Psychological and biological factors in post - infective gut dysfunction. *Gut* 1999; 44: 400 - 6
11. Mayer EA, Raybould HE. Role of visceral afferent mechanisms in functional bowel disorders. *Gastroenterology* 1990; 99: 1688 - 704
12. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared to subjects without bowel dysfunction. *Gut* 1992; 33: 825 - 30
13. Talley NJ, Axon A, Bytzer P, Holtmann A, Lam A, S Velouhuyzen van Zanten. Management of uninvestigated and functional dyspepsia: a working party report for the World Congress of Gastroenterology 1998. *Aliment Pharmacol Ther* 1999; 13: 1135 - 48
14. Adang RP, Vismans JF, Talmon JL, Hassman A, Amberger AW, Stockbrugger RW. Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. *Gastroint Endosc* 1995; 42: 390 - 7
15. Horrocks JC, De Dombal FT. Clinical presentation of patients with 'dyspepsia'. Detailed symptomatic study of 360 patients. *Gut* 1978; 19: 19 - 26
16. McColl KEL, Murray LS, EL - Omar E, Dickson A, EL - Nujumia A, Hilditch T, et al. Symptomatic benefit from eradication *Helicobacter pylori* infection in patients with nonulcer dyspepsia. *N Engl J Med* 1998; 339: 1867 - 74
17. Blum AL, Talley NJ, O'Morian C, Van Zanten SV, Labenz J, Junghard O, et al. Lack of effect of treating *Helicobacter pylori* infection in patients with nonulcer dyspepsia. *N Engl J Med* 1998; 339: 1875 - 81
18. Talley NJ, Jassens J, Lauritsen K, Racz I, Bolling - Sternevald E. Eradication of *Helicobacter pylori* in functional dyspepsia: randomized double blind placebo controlled trial with 12 months' follow up. *BMJ* 1999; 318: 833 - 7
19. Talley NJ, Vakil N, Ballard ED, Fennerty MB. Absence of benefit of eradication *Helicobacter pylori* in patients with nonulcer dyspepsia. *N Engl J Med* 1999; 341: 1106 - 11
20. Greydanus M, Vassallo M, Camilleri M, Nelson DK, Hanson RB, Thomforde GM. Neurohormonal factors in functional dyspepsia: insights on pathophysiological mechanisms. *Gastroenterol* 1991; 100: 1311 - 8
21. NIH Consensus Conference. *Helicobacter pylori* in peptic ulcer disease. *JAMA* 1994; 272: 65 - 9
22. Joshua JO, Jeff E, Steven F, Katherine LK, Andrew HS.

- Management strategies for *Helicobacter pylori* - seropositive patients with dyspepsia: Clinical and economic consequences. *Annals of Internal Medicine* 1997; 126: 280 - 91
23. Delaney DC. Role of *Helicobacter pylori* in gastrointestinal disease: implications for primary care of dyspepsia. *Br J Gen Pract* 1995; 45: 489
24. Sander JO, Veldhuyzen VZ, Cynthia C. Drug treatment of functional dyspepsia: a systemic analysis of trial methodology with recommendations for design of future trials. *Am J Gastroenterol* 1996; 91: 660
25. Delattre M, Malesloy M, Prinzie A. Symptomatic treatment of non - ulcer dyspepsia with cimetidine. *Curr Ther Res* 1985; 37: 980
26. Berstad A, Wilhelmsen I. Gastric accommodation in functional dyspepsia. *Scand J Gastroenterol* 1997; 32: 193 - 7
27. Talley NJ. Functional dyspepsia - should treatment be targeted on disturbed physiology? *Aliment Pharmacol Ther* 1995; 9: 107 - 15
28. Heyse PM, Rambaldo R, Hazelhoff B. Factors affecting short - and long - term outcome of a short therapeutic trial with cisapride in dyspeptic patients. *Scand J Gastroenterol* 1993; 195: 15 - 23
29. Drossman DA, Corraziari E, Talley NJ. The functional gastrointestinal disorders. 2nd eds. McLean: Degnon Associates, 2000
30. Moss HE, Sanger GJ. The effects of granisetron, ICS 205 - 930 and ondansetron on the visceral pain reflex induced by duodenal distension. *Br J Pharmacol* 1990; 100: 497 - 501
31. Wilmer A, Tack J, Coremans G. Effect of ondansetron, a 5 - HT₃ antagonist on perception of gastric distension and gastric compliance in healthy man(abstr). *Gastroenterology* 1993; 104: A603
32. Stark M Jr, Maher K, Gupta P. Visceral afferent blockade with ondansetron with noncardiac chest pain(abstr). *Am J Gastroenterol* 1991; 86: 1305
33. Talley NJ. 5 - Hydroxytryptamine agonists and antagonists in the motility and sensation: clinical implications. *Aliment Pharmacol Ther* 1992; 6: 273 - 89
34. Resd NW, Bardhan KD, Whorwell PJ. Fedotozine in functional dyspepsia: results of a 6 - week placebo - controlled multicenter therapeutic trial(abstr). *Gastroenterology* 1995; 108: A676
35. Li Y, Han JS. Cholegystokinin octapeptide antagonizes morphine analgesia in periaqueductal gray of the rat. *Brain Res* 1989; 480: 105 - 10
36. Boulant J, Fioramonti J, Dapoigny M, Bommelear G, Bueno L. Cholegystokinin and nitric oxide in transient lower esophageal sphincter relaxation to gastric distension in dogs. *Gastroenterology* 1994; 107: 1059 - 66
37. Bradette M, Delvaux M, Stsumont G, Fioramonti J, Bueno L, Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. *Dig Dis Sci* 1994; 39: 1171 - 8